Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
Revenue of Tyra Biosciences, Inc. (TYRA)
Revenue in 2023 (TTM): $
According to Tyra Biosciences, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Tyra Biosciences, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-353,000 | $-79,592,000 | $-69,134,000 | $-69,134,000 |
| 2022 | $ | $-296,000 | $-58,631,000 | $-55,325,000 | $-51,723,000 |
| 2021 | $ | $-140,000 | $-26,148,000 | $-26,294,000 | $-26,141,000 |
| 2020 | $ | $-47,000 | $-9,250,000 | $-9,336,000 | $-9,314,000 |
| 2019 | $ | $-8,000 | $-3,114,000 | $-4,065,000 | $-4,058,000 |